Science
The health effects of several strains of probiotics, including the bacterial species in Zoguri, have been extensively researched and documented in numerous peer-reviewed studies. We invite you to delve into the science and studies behind each of these benefits below.
Digestive Support in IBS and Reduces Symptoms of Anxiety
STUDY NAME: Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial
👥NUMBER OF PARTICIPANTS: 140 adults aged 18 years to 65 years
📝STUDY DESIGN: A randomized, double-blind, placebo-controlled clinical trial was conducted in participants with a diagnosis of IBS (based on the Rome IV criteria).
🎯STUDY GOAL: The aim of the study was to demonstrate the efficacy and safety of Limosilactobacillus reuteri (L. reuteri) DSM 17938 combined with L. reuteri ATCC PTA 6475 regarding improving the symptoms associated with IBS in adults.
📝CONCLUSION: A twice-a-day intervention of Limosilactobacillus reuteri (L. reuteri) DSM 17938 combined with L. reuteri ATCC PTA 6475 for 14 weeks is safe and effective, reduces the symptoms associated with IBS in adults aged 18 years to 65 years, improves stool consistency, and reduces symptoms associated with anxiety after 6 weeks.
Digestive Support in Constipation
STUDY NAME: Randomized, double-blind, placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation
👥NUMBER OF PARTICIPANTS: 56 Functional Constipation (FC) patients with normal colonic transit time and without anorectal disorders and pelvic floor dysfunctions completed the study.
📝STUDY DESIGN: Lactobacillus reuteri (LR) DSM 17938 was administered for 105 days in a randomized double-blind clinical trial (28 patients per arm). Individual and cumulative scores including the Constipaq, a modified Constipation Scoring System (CSS) that considers the patient assessment of constipation-QoL (PAC-QoL), were calculated during the preliminary visit (V0), at day 15 (end of the induction period with a LR DSM 17938 double dosage, 4×108 cfu), day 60 (intermediate evaluation) and day 105 (V4) after a standard dosage (2×108 cfu).
🎯STUDY GOAL: The aim of the study was to investigate the effects of a long-lasting administration of L. reuteri DSM 17938 (LR DSM 17938) on symptoms and quality of life (QoL) score in patients with functional constipation (FC).
📝CONCLUSION: At the end of treatment, the beneficial effect of LR DSM 17938 compared to placebo was significantly evident for symptoms related to gas content and dysbiosis (abdominal discomfort, pain and bloating), incomplete defecation and helps for defecation (P<0.05). At the end of the whole LR DSM 17938 treatment, a marked and positive effect on both the CSS single and the cumulative items was evident with the exception of unfruitful attempt and Bristol score. Present findings indicate that LR DSM 17938 has an effect on symptoms different from stool consistency, and they suggest that this probiotic can effectively be used in association therapy rather than as single-drug therapy in the management of FC.
Health Support Prevention in Infants
STUDY NAME: Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938
👥NUMBER OF PARTICIPANTS: 138 infants were assessed for eligibility; 113 ones underwent randomisation and 105 completed the study
📝STUDY DESIGN: This was a single blinded, prospective randomized, controlled, parallel-group study conducted in North-West Italy. Parent and clinicians, but not the Trial Outcome Assessor (TOA) knew medication type. The local ethics committee (Comitato Interaziendale AA.SS.OO. O.I.R.M./S. Anna-Ordine Mauriziano di Torino) approved the study before the start, and written informed consent was obtained from parents by pediatrician before inclusion of the infants in the study. Parents received information about the study during the first pediatric consultation (within 10 days of life). In case of interest, parents were provided detailed information concerning infantile colic, how to recognize it and the available treatment by the pediatrician. However, pediatricians did not explain the potential effect of the probiotic in order not to influence parental observations.
🎯STUDY GOAL: They tested the hypothesis that an early administration of L. reuteri to newborns could reduce:
- the use of pain-relieving drugs (cimetropium bromide and simethicone) to treat infantile colic during the first 3 months of life;
- the supply of infant formulas (formulas containing probiotics were not allowed);
- the number of calls to the pediatrician due to infantile colic;
- the number of visits at pediatrician’s ambulatory due to infantile colic.
📝CONCLUSION: The study demonstrated that L. reuteri DSM 17938 with vitamin D3 daily administered significantly reduced the use of pain-relieving agents, such as simethicone and cimetropium bromide (registered by parents through a diary) and the number of phone calls and visits for colic registered by physician, compared to vitamin D3 only. The treatment group showed a lower number of pediatric consultations related to episodes of infant colic than the control group (P<0001).
Observed data concerning the use of infant formulas are really interesting: it is well known that infantile colic is one of the main reasons to switch formula (Forsyth et al., 1985; Iacovou et al., 2012; Polack et al., 1999) and we have registered how the administration of L. reuteri with vitamin D3 may reduce the use of artificial formulas in exclusively breastfed infants. Therefore, the probability to become a partially breastfed infant is significantly lower in the treated group of infants.
Health Support Prevention in Infants
STUDY NAME: Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial
👥NUMBER OF PARTICIPANTS: 589 Infants were randomly allocated to receive L. reuteri DSM 17938 or placebo daily for 90 days.
📝STUDY DESIGN: A prospective, multicentered, double-blinded, placebo-controlled randomized clinical trial was performed on term newborns (age <1 week) born at 9 different neonatal units in Italy.
🎯STUDY GOAL: To investigate whether oral supplementation with Lactobacillus reuteri DSM 17938 during the first 3 months of life can reduce the following:
- Onset of colic, GER, and constipation in term newborns.
- Socioeconomic impact of these conditions.
📝CONCLUSION: Prophylactic use of L. reuteri DSM 17938 during the first 3 months of life reduced the onset of functional gastrointestinal disorders and reduced private and public costs for the management of this condition. At 3 months of age, the mean duration of crying time (38 vs 71 minutes; P < .01), the mean number of regurgitations per day (2.9 vs 4.6; P < .01), and the mean number of evacuations per day (4.2 vs 3.6; P < .01) for the L reuteri DSM 17938 and placebo groups, respectively, were significantly different.
Reduction of Bone Loss in Older Women
STUDY NAME: Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial
👥NUMBER OF PARTICIPANTS: Seventy women completed the study. L. reuteri 6475 reduced loss of total vBMD compared to placebo.
📝STUDY DESIGN: Double-blind, placebo-controlled study, women from the population who were 75 to 80 years old and had low BMD were randomized to orally receive 1010 colony-forming units of L. reuteri 6475 daily or placebo.
🎯STUDY GOAL: The objective of this trial was to investigate if L. reuteri 6475 affects bone loss in older women with low BMD. The predefined primary end-point was relative change after 12 months in tibia total volumetric BMD (vBMD).
📝CONCLUSION: In this randomized, placebo-controlled, double-blind, clinical trial, supplementation with L. reuteri 6475 for 12 months resulted in reduced bone loss in older women with low bone density. The reduction in total vBMD in the distal tibia was nearly half as large in women taking 1x1010 CFU day−1 of L. reuteri 6475 than in women taking placebo.
Modulation in Gut Microbiota Health and Bone Formation at 1 Year
STUDY NAME: One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density
👥NUMBER OF PARTICIPANTS: 20 elderly women by identifying ten women with a good response (GR group) and ten women with a poor response (PR group) from the per protocol (PP) population as previously described.
📝STUDY DESIGN: Women with a good response (GR group, n = 10) and with a poor response (PR group, n = 10) were recruited. Serum samples and fecal samples were collected from the older women with bone loss at baseline and 12 months. The complete metabolomic profiling for these women were performed.
🎯STUDY GOAL: To investigate differences in subjects with different responses to supplementation with the probiotic strain L. reuteri ATCC PTA 6475
📝CONCLUSION: The study observed a significantly increased gene richness, enrichment of short-chain fatty acids (SCFAs) producing species as well as depletion of E. coli and its biofilm formation in the GR group, by investigating alterations of the gut microbiome during 1 year L. reuteri ATCC PTA 6475 supplementation. This indicates that L. reuteri ATCC PTA 6475 supplementation might promote bone formation by modulating the gut microbiota composition and function
Immune Support for Workers
STUDY NAME: Increasing work-place healthiness with the probiotic Lactobacillus reuteri: A randomized, double-blind placebo-controlled study
👥NUMBER OF PARTICIPANTS: 181 subjects complied with the study protocol, 94 were randomized to receive L. reuteri and 87 received placebo.
📝STUDY DESIGN: The volunteers were randomized in a double-blind fashion to take a daily probiotic drinking straw together with at least 100 ml liquid. Each straw delivered 108 Colony Forming Units (CFU) of L. reuteri protectis, ATCC55730 or placebo.
🎯STUDY GOAL: This study examined the effect of the probiotic Lactobacillus reuteri protectis (ATCC55730) on its ability to improve work-place healthiness by reducing short term sick-leave caused by respiratory or gastrointestinal infections.
📝CONCLUSION: In the placebo group 26.4% reported sick-leave for the defined causes during the study as compared with 10.6% in the L. reuteri group (p < 0.01). The frequency of sick-days was 0.9% in the placebo group and 0.4% in the L. reuteri group (p < 0.01). Among the 53 shift-workers, 33% in the placebo group reported sick during the study period as compared with none in the L. reuteri group(p < 0.005).
Immune Support for Diarrhea and Upper Respiratory School Children
STUDY NAME: Diarrhea in Preschool Children and Lactobacillus reuteri: A Randomized Controlled Trial
👥NUMBER OF PARTICIPANTS: 336 healthy children aged between 6 and 36 months in Mexico were randomly assigned to receive L. reuteri DSM 17938 orally or an identical placebo.
📝STUDY DESIGN: To evaluate whether daily administration of Lactobacillus reuteri DSM 17938 reduces the frequency and duration of diarrheal episodes and other health outcomes in day school children in Mexico.
🎯STUDY GOAL: Healthy children (born at term, aged 6–36 months) attending day care centers were enrolled in this randomized, double-blind, placebo-controlled trial. They received L. reuteri DSM 17938 (dose 108 colony-forming unit; n = 168) or identical placebo (n = 168) by mouth, daily for 3 months, after which they were followed-up after a further 3 months without supplementation.
📝CONCLUSION: Data from all children were included in the final analysis. L. reuteri DSM 17938 significantly reduced the frequency and duration of episodes of diarrhea and respiratory tract infection at both 3 and 6 months (P < .05). Additionally, the number of doctor visits, antibiotic use, absenteeism from day school and parental absenteeism from work were significantly reduced in the L. reuteri group (P < .05). A cost-benefit analysis revealed significant reductions in costs in the L. reuteri-treated children. No adverse events related to the study product were reported.
